Campbell Shannon reported grant involving 114,200 shares of Zentalis Pharmaceuticals, Inc. at $0.00 for $0 on May 26, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed May 27, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$0Shares × reported price
Shares traded
114,200Common Stock
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
114,200Direct
Trade date
May 26, 2026Grant
Filed
May 27, 2026, 4:11 PM ET1-day reporting delay
Accession
0002018966-26-000005Code A · Transaction 88263
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

ZNTL price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ZNTL · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −0.7%1w ago −12%1d ago +1%
Returns since7d −7.2%30d +0.7%90d −5.2%180d1y

Footnotes in full

F1: The restricted stock units ("RSUs") were granted by the Issuer pursuant to the Issuer's Non-Employee Director Compensation Program. One third of the RSUs will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.